Prostate News and Research

RSS

Researchers develop new approach to immunotherapy of cancer

Harnessing the immune system is emerging as one of the most promising new ways to fight cancer. Most cancer cells are eliminated by the immune system; however, over a lifetime, a few may escape this immune surveillance and lead to tumors and metastases. Hence a formidable opportunity has been to find ways to make the immune system recognize the tumor as a foreign body and trigger a response.

13 May 2010

Robotic surgery keeps features intact in head, neck cancer removal procedures

Surgeons who perform procedures to remove head and neck cancers often work for six to eight hours on what is typically major, invasive surgery, which many times comes with facial disfigurement and debilitating side effects for the patient.

13 May 2010

Researchers develop new technology to manage prostate cancer treatment

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

13 May 2010

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

SRI International, an independent nonprofit research and development organization, announced today that researchers have developed an anti-angiogenic molecule SR16388 that has demonstrated preclinical antitumor activity against multiple myeloma.

12 May 2010

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

If you have asthma or eczema, your hyper reactive immune system may lower your risk of some of the most common types of cancer, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Medical options to help prostate cancer patients make informed treatment decisions

While the dreaded words "You have prostate cancer" often leave patients confused, the impact of the diagnosis can extend to the entire family, especially wives, says a top expert.

10 May 2010

Experts to present latest research on prostate cancer and related conditions

WHAT: This symposium features a renowned faculty of clinicians and researchers who will present leading-edge information on the best standards of care in managing the full spectrum of prostate cancer and related conditions.

10 May 2010

Merrion Pharmaceuticals increases patent protection for Orazol

Merrion Pharmaceuticals plc, a pharmaceutical development company, today announces that it has been granted a further U.S. Patent, increasing the protection for their lead product, Orazol™.

7 May 2010

Preoperative MRI helps spare erectile function, continence after RALP for prostate cancer

Preoperative prostate magnetic resonance imaging (MRI) can help urologic surgeons spare the neurovascular bundle (NVB) (which controls a man's erectile function and continence) during a robotic assisted laparoscopic prostatectomy (RALP) for the treatment of prostate cancer, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

7 May 2010

A checklist to stay healthy at every age

Shantanu Nundy, MD, a second-year resident in internal medicine at the University of Chicago Medical Center may soon find out. Driven by his mother's health questions and the difficulty of providing simple, reliable answers, Nundy collected all of the "generally accepted truths" about preventing disease, organized them into checklists based on age, and persuaded the Johns Hopkins University Press to publish them as Stay Healthy at Every Age: What Your Doctor Wants you to Know.

7 May 2010

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Genomic Health, Inc. today reported financial results and business progress for the quarter ended March 31, 2010.

6 May 2010

Endo Pharmaceuticals signs agreement to acquire HealthTronics

Continuing to diversify, move into new growth areas beyond pharmaceuticals, and strengthen its commitment to improved patient outcomes in urology, Endo Pharmaceuticals today announced that it has signed an agreement to acquire HealthTronics, Inc., a leading U.S. provider of urological products and services.

6 May 2010

FDA approves Provenge for treating men with advanced prostate cancer

The US Food and Drug Administration has approved a new 'cancer vaccine' for treating men with advanced prostate cancer.

6 May 2010

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.

6 May 2010

Canadian Cancer Society awards London scientists new funds for innovative research

Three London scientists are receiving new funding from the Canadian Cancer Society for their work in innovative cancer research.

5 May 2010

Myriad Genetics' third-quarter fiscal 2010 revenues increase 5% to $90.8M

Myriad Genetics, Inc. today reported financial results for the third fiscal quarter and the nine-month period ended March 31, 2010.

5 May 2010

Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH

Nymox Pharmaceutical Corporation today announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 ½ years after a single treatment with NX-1207.

5 May 2010

Theragenics reports highest quarterly consolidated revenue of $20.3 million

Theragenics Corporation®, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the first quarter ended March 31, 2010.

4 May 2010

Prostate News and Research

Researchers develop new approach to immunotherapy of cancer

Robotic surgery keeps features intact in head, neck cancer removal procedures

Researchers develop new technology to manage prostate cancer treatment

Researchers develop anti-angiogenic molecule SR16388 for treatment of MM

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Medical options to help prostate cancer patients make informed treatment decisions

Experts to present latest research on prostate cancer and related conditions

Merrion Pharmaceuticals increases patent protection for Orazol

Preoperative MRI helps spare erectile function, continence after RALP for prostate cancer

A checklist to stay healthy at every age

Genomic Health reports 22% revenue growth, 58% decrease in net loss for first-quarter 2010

Endo Pharmaceuticals signs agreement to acquire HealthTronics

FDA approves Provenge for treating men with advanced prostate cancer

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Canadian Cancer Society awards London scientists new funds for innovative research

Myriad Genetics' third-quarter fiscal 2010 revenues increase 5% to $90.8M

Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH

Theragenics reports highest quarterly consolidated revenue of $20.3 million

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News